Neurology 2 plex b kit

Manufactured by Quanterix

Sourced in United States

The Neurology 2-Plex B kit is a laboratory equipment product designed for the detection and quantification of two specific proteins in biological samples. The kit utilizes the Simoa technology, a highly sensitive immunoassay platform, to provide accurate and reliable results. The core function of this product is to enable researchers and clinicians to measure the levels of these proteins, which are often associated with neurological conditions.

Automatically generated - may contain errors

Lab products found in correlation

Simoa hd 1, by Quanterix (1 mentions) P tau181 advantage v2 kit, by Quanterix (1 mentions)

Close spelling variants of this product

Neurology 2-Plex B

4 protocols using neurology 2 plex b kit

Quantifying Plasma Tau-217 and Neurodegeneration Markers

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Non‐fasting, morning blood samples were obtained by venipuncture and processed for plasma. Plasma p‐tau217 concentrations were measured using a novel single‐molecule array (Simoa) assay developed by Janssen Research and Development.
⁴ (link),
²⁴ ,
²⁵ (link) The functional plasma p‐tau217 assay range, accounting for sample dilution, was: lower limit of detection (LLOD) = 0.0011 pg/mL, lower limit of quantification (LLOQ) = 0.0187 g/mL, upper limit of quantification (ULOQ) = 10 pg/mL. All samples were > LLOD. GFAP and NfL concentrations were measured using the Neurology 2‐Plex B kit (Quanterix Simoa). Samples were measured in duplicate and all participants eligible for the present analysis had samples with coefficients of variance (CV) < 20%. Mean ± standard deviation CV% for study samples was 4.4% ± 3.4% (p‐tau217), 4.6% ± 3.7% (GFAP) and 4.8% ± 7.7% (NfL).

Saloner R., VandeVrede L., Asken B.M., Paolillo E.W., Gontrum E.Q., Wolf A., Lario‐Lago A., Milà‐Alomà M., Triana‐Baltzer G., Kolb H.C., Dubal D.B., Rabinovici G.D., Miller B.L., Boxer A.L., Casaletto K.B, & Kramer J.H. (2023). Plasma phosphorylated tau‐217 exhibits sex‐specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults. Alzheimer's & Dementia, 20(1), 376-387.

+ Open protocol

+ Expand

Quantifying Neurological Biomarkers via Simoa

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum samples were collected at each visit and stored at −80°C. NfL and GFAP levels were measured using the Neurology 2‐Plex B kit from Quanterix on a Simoa HD‐X analyzer® according to the manufacturer's instructions. All samples were measured in duplicates, with the same kit lot, at the same machine by a lab technician blinded to the clinical characteristics. The intra‐assay coefficient of variation (CV) of all samples was <20% (few measurements had to be replicated). Quality control samples were included at each run with inter‐assay CV <20%. Age‐adjusted z scores for NfL and GFAP were generated using large reference datasets as described before.
¹ (link),
² (link) Here, Z scores measure deviation from healthy controls: for example, a biomarker Z score of 1 means that the concentration deviates by 1 standard deviation from values in the reference database adjusted for relevant physiological factors.

Abdelhak A., Antweiler K., Kowarik M.C., Senel M., Havla J., Zettl U.K., Kleiter I., Skripuletz T., Haarmann A., Stahmann A., Huss A., Gingele S., Krumbholz M., Benkert P., Kuhle J., Friede T., Ludolph A.C., Ziemann U., Kümpfel T, & Tumani H. (2023). Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. Annals of Clinical and Translational Neurology, 11(2), 477-485.

+ Open protocol

+ Expand

Measurement of NfL and GFAP in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured using single molecular array technology with an ultrahigh sensitivity protein molecular detection instrument (Simoa HD-1, Quanterix, MA, USA) with a Neurology 2-Plex B kit (502713, Quanterix, MA, USA) according to a previously described procedure [30 (link)].

Xu J., Xia Y., Meng M., Liu F., Che P., Zhang Y., Wang Y., Cai L., Qin W, & Zhang N. (2023). Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation. Alzheimer's Research & Therapy, 15, 21.

+ Open protocol

+ Expand

Plasma biomarkers for Alzheimer's Disease detection

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were centrifuged immediately after draw and stored at −80°C. Plasma Aβ42/40 was determined by the Quest AD‐Detect, beta–amyloid 42/40 ratio, plasma test (Quest Diagnostics, San Juan Capistrano, CA; test code: 11786), which uses high‐throughput liquid chromatography/tandem mass spectrometry (LC‐MS/MS). MS‐based approaches have yielded improved classification between Aβ PET negative and positive participants compared to immunoassays.
⁶ (link) An initial clinical validation study of the Quest AD‐Detect plasma test demonstrated high AUC for differentiating Aβ PET positive from PET negative individuals
³⁸ (link) and comparable performance to other validated MS‐based assays.
³ (link),
⁴ (link),
⁵ (link),
⁶ (link) Other plasma biomarkers, including t‐tau (N3PA Advantage Kit, Item #101995), p‐tau181 (pTau‐181 Advantage V2 kit, Item #103714), NfL and GFAP (Neurology 2‐Plex B kit, Item #103520), were analyzed using single‐molecule array immunoassays (Quanterix Corporation, Lexington, MA).
³⁹ (link)

DeSimone J.C., Wang W., Loewenstein D.A., Duara R., Smith G.E., McFarland K.N., Armstrong M.J., Weber D.M., Barker W., Coombes S.A, & Vaillancourt D.E. (2024). Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia. Alzheimer's & Dementia, 20(4), 2830-2842.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!